C
Basilea Pharmaceutica AG
BPMUF
$54.00
$1.172.22%
C
Hold
3/24/2025Upgraded
Basilea Pharmaceutica AG (BPMUF) was upgraded to C from C- on 3/24/2025 due to an increase in the volatility index.
Basilea Pharmaceutica AG (BPMUF) was upgraded to C from C- on 3/24/2025 due to an increase in the volatility index.
C
Hold
3/6/2025Downgrade
Basilea Pharmaceutica AG (BPMUF) was downgraded to C- from C on 3/6/2025 due to a decline in the total return index.
Basilea Pharmaceutica AG (BPMUF) was downgraded to C- from C on 3/6/2025 due to a decline in the total return index.
C
Hold
2/19/2025Upgraded
Basilea Pharmaceutica AG (BPMUF) was upgraded to C from C- on 2/19/2025 due to a significant increase in the valuation index, growth index and efficiency index.
Basilea Pharmaceutica AG (BPMUF) was upgraded to C from C- on 2/19/2025 due to a significant increase in the valuation index, growth index and efficiency index.
C
Hold
10/17/2024Upgraded
Basilea Pharmaceutica AG (BPMUF) was upgraded to C- from D+ on 10/17/2024 due to an increase in the total return index and volatility index.
Basilea Pharmaceutica AG (BPMUF) was upgraded to C- from D+ on 10/17/2024 due to an increase in the total return index and volatility index.
D
Sell
8/16/2024Downgrade
Basilea Pharmaceutica AG (BPMUF) was downgraded to D+ from C on 8/16/2024 due to a significant decline in the growth index, valuation index and efficiency index. Total revenue declined 3.31% from $43.63M to $42.18M, operating cash flow declined 3.31% from $10.25M to $9.91M, and EBIT declined 3.31% from $5.44M to $5.26M.
Basilea Pharmaceutica AG (BPMUF) was downgraded to D+ from C on 8/16/2024 due to a significant decline in the growth index, valuation index and efficiency index. Total revenue declined 3.31% from $43.63M to $42.18M, operating cash flow declined 3.31% from $10.25M to $9.91M, and EBIT declined 3.31% from $5.44M to $5.26M.
C
Hold
8/15/2024Upgraded
Basilea Pharmaceutica AG (BPMUF) was upgraded to C from C- on 8/15/2024 due to a large increase in the volatility index and total return index.
Basilea Pharmaceutica AG (BPMUF) was upgraded to C from C- on 8/15/2024 due to a large increase in the volatility index and total return index.
C
Hold
5/9/2024Upgraded
Basilea Pharmaceutica AG (BPMUF) was upgraded to C- from D+ on 5/9/2024 due to an increase in the total return index, efficiency index and volatility index. Total capital increased 8.6% from $129.69M to $140.85M, and net income increased 0.25% from -$12.11M to -$12.08M.
Basilea Pharmaceutica AG (BPMUF) was upgraded to C- from D+ on 5/9/2024 due to an increase in the total return index, efficiency index and volatility index. Total capital increased 8.6% from $129.69M to $140.85M, and net income increased 0.25% from -$12.11M to -$12.08M.
D
Sell
2/6/2024Downgrade
Basilea Pharmaceutica AG (BPMUF) was downgraded to D+ from C- on 2/6/2024 due to a decline in the total return index, volatility index and efficiency index.
Basilea Pharmaceutica AG (BPMUF) was downgraded to D+ from C- on 2/6/2024 due to a decline in the total return index, volatility index and efficiency index.
C
Hold
12/18/2023Downgrade
Basilea Pharmaceutica AG (BPMUF) was downgraded to C- from C on 12/18/2023 due to a decline in the volatility index, total return index and efficiency index.
Basilea Pharmaceutica AG (BPMUF) was downgraded to C- from C on 12/18/2023 due to a decline in the volatility index, total return index and efficiency index.
C
Hold
8/16/2023Upgraded
Basilea Pharmaceutica AG (BPMUF) was upgraded to C from C- on 8/16/2023 due to a significant increase in the valuation index, solvency index and growth index. Total revenue increased 2.94% from $45.88M to $47.23M, operating cash flow increased 2.94% from $11.81M to $12.16M, and EBIT increased 2.94% from $20.69M to $21.29M.
Basilea Pharmaceutica AG (BPMUF) was upgraded to C from C- on 8/16/2023 due to a significant increase in the valuation index, solvency index and growth index. Total revenue increased 2.94% from $45.88M to $47.23M, operating cash flow increased 2.94% from $11.81M to $12.16M, and EBIT increased 2.94% from $20.69M to $21.29M.
C
Hold
7/27/2023Downgrade
Basilea Pharmaceutica AG (BPMUF) was downgraded to C- from C on 7/27/2023 due to a noticeable decline in the total return index and volatility index.
Basilea Pharmaceutica AG (BPMUF) was downgraded to C- from C on 7/27/2023 due to a noticeable decline in the total return index and volatility index.
C
Hold
5/15/2023Upgraded
Basilea Pharmaceutica AG (BPMUF) was upgraded to C from D+ on 5/15/2023 due to an increase in the total return index, volatility index and valuation index.
Basilea Pharmaceutica AG (BPMUF) was upgraded to C from D+ on 5/15/2023 due to an increase in the total return index, volatility index and valuation index.
D
Sell
5/1/2023Downgrade
Basilea Pharmaceutica AG (BPMUF) was downgraded to D+ from C- on 5/1/2023 due to a decline in the volatility index, efficiency index and growth index.
Basilea Pharmaceutica AG (BPMUF) was downgraded to D+ from C- on 5/1/2023 due to a decline in the volatility index, efficiency index and growth index.
C
Hold
4/3/2023Downgrade
Basilea Pharmaceutica AG (BPMUF) was downgraded to C- from C on 04/03/2023.
Basilea Pharmaceutica AG (BPMUF) was downgraded to C- from C on 04/03/2023.
C
Hold
2/15/2023Upgraded
Basilea Pharmaceutica AG (BPMUF) was upgraded to C from C- on 2/15/2023 due to a large increase in the solvency index, valuation index and efficiency index. Total capital increased 6.14% from $169.57M to $179.98M, and net income increased 0.38% from $12.6M to $12.65M.
Basilea Pharmaceutica AG (BPMUF) was upgraded to C from C- on 2/15/2023 due to a large increase in the solvency index, valuation index and efficiency index. Total capital increased 6.14% from $169.57M to $179.98M, and net income increased 0.38% from $12.6M to $12.65M.
C
Hold
12/21/2022Upgraded
Basilea Pharmaceutica AG (BPMUF) was upgraded to C- from D+ on 12/21/2022 due to a noticeable increase in the volatility index and total return index.
Basilea Pharmaceutica AG (BPMUF) was upgraded to C- from D+ on 12/21/2022 due to a noticeable increase in the volatility index and total return index.
D
Sell
8/18/2022Upgraded
Basilea Pharmaceutica AG (BPMUF) was upgraded to D+ from D on 8/18/2022 due to a substantial increase in the efficiency index, growth index and total return index. Net income increased 4.25% from -$6.61M to -$6.32M, EBIT increased 4.25% from -$4.22M to -$4.04M, and earnings per share increased from -$0.5579 to -$0.5342.
Basilea Pharmaceutica AG (BPMUF) was upgraded to D+ from D on 8/18/2022 due to a substantial increase in the efficiency index, growth index and total return index. Net income increased 4.25% from -$6.61M to -$6.32M, EBIT increased 4.25% from -$4.22M to -$4.04M, and earnings per share increased from -$0.5579 to -$0.5342.
D
Sell
5/16/2022Upgraded
Basilea Pharmaceutica AG (BPMUF) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Basilea Pharmaceutica AG (BPMUF) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Basilea Pharmaceutica AG (BPMUF) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
Basilea Pharmaceutica AG (BPMUF) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
D
Sell
5/4/2022Upgraded
Basilea Pharmaceutica AG (BPMUF) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
Basilea Pharmaceutica AG (BPMUF) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Basilea Pharmaceutica AG (BPMUF) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
Basilea Pharmaceutica AG (BPMUF) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/21/2022Upgraded
Basilea Pharmaceutica AG (BPMUF) was upgraded to D from E+ on 04/21/2022.
Basilea Pharmaceutica AG (BPMUF) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Basilea Pharmaceutica AG (BPMUF) was downgraded to E+ from D on 4/20/2022 due to a noticeable decline in the total return index, volatility index and valuation index.
Basilea Pharmaceutica AG (BPMUF) was downgraded to E+ from D on 4/20/2022 due to a noticeable decline in the total return index, volatility index and valuation index.
D
Sell
3/24/2021Downgrade
Basilea Pharmaceutica AG (BPMUF) was downgraded to D from D+ on 3/24/2021 due to a decline in the total return index and volatility index.
Basilea Pharmaceutica AG (BPMUF) was downgraded to D from D+ on 3/24/2021 due to a decline in the total return index and volatility index.
D
Sell
2/18/2021Downgrade
Basilea Pharmaceutica AG (BPMUF) was downgraded to D+ from C- on 2/18/2021 due to a significant decline in the efficiency index and growth index. Net income declined 1.72% from -$13.41M to -$13.64M, operating cash flow declined 1.72% from -$11.4M to -$11.59M, and EBIT declined 1.72% from -$10.96M to -$11.15M.
Basilea Pharmaceutica AG (BPMUF) was downgraded to D+ from C- on 2/18/2021 due to a significant decline in the efficiency index and growth index. Net income declined 1.72% from -$13.41M to -$13.64M, operating cash flow declined 1.72% from -$11.4M to -$11.59M, and EBIT declined 1.72% from -$10.96M to -$11.15M.
C
Hold
1/15/2021Upgraded
Basilea Pharmaceutica AG (BPMUF) was upgraded to C- from D+ on 1/15/2021 due to an increase in the volatility index and total return index.
Basilea Pharmaceutica AG (BPMUF) was upgraded to C- from D+ on 1/15/2021 due to an increase in the volatility index and total return index.
D
Sell
8/13/2020Upgraded
Basilea Pharmaceutica AG (BPMUF) was upgraded to D+ from D on 8/13/2020 due to a large increase in the efficiency index, growth index and total return index. Total capital increased 1.74% from $125.93M to $128.12M, net income increased 0.41% from $5.14M to $5.16M, and total revenue increased 0.41% from $35.83M to $35.98M.
Basilea Pharmaceutica AG (BPMUF) was upgraded to D+ from D on 8/13/2020 due to a large increase in the efficiency index, growth index and total return index. Total capital increased 1.74% from $125.93M to $128.12M, net income increased 0.41% from $5.14M to $5.16M, and total revenue increased 0.41% from $35.83M to $35.98M.
D
Sell
2/19/2020Downgrade
Basilea Pharmaceutica AG (BPMUF) was downgraded to D from D+ on 2/19/2020 due to a decline in the growth index, valuation index and solvency index. Debt to equity increased from -2.15 to -2.08, and total revenue declined 0.41% from $36.11M to $35.97M.
Basilea Pharmaceutica AG (BPMUF) was downgraded to D from D+ on 2/19/2020 due to a decline in the growth index, valuation index and solvency index. Debt to equity increased from -2.15 to -2.08, and total revenue declined 0.41% from $36.11M to $35.97M.
D
Sell
2/4/2020Upgraded
Basilea Pharmaceutica AG (BPMUF) was upgraded to D+ from D on 2/4/2020 due to an increase in the volatility index, total return index and valuation index.
Basilea Pharmaceutica AG (BPMUF) was upgraded to D+ from D on 2/4/2020 due to an increase in the volatility index, total return index and valuation index.
D
Sell
3/1/2018Upgraded
Basilea Pharmaceutica AG (BPMUF) was upgraded to D from D- on 3/1/2018 due to a noticeable increase in the efficiency index and growth index.
Basilea Pharmaceutica AG (BPMUF) was upgraded to D from D- on 3/1/2018 due to a noticeable increase in the efficiency index and growth index.
D
Sell
11/29/2017Downgrade
Basilea Pharmaceutica AG (BPMUF) was downgraded to D- from D on 11/29/2017 due to a decline in the efficiency index and valuation index. Net income declined 1.95% from -$10.25M to -$10.45M.
Basilea Pharmaceutica AG (BPMUF) was downgraded to D- from D on 11/29/2017 due to a decline in the efficiency index and valuation index. Net income declined 1.95% from -$10.25M to -$10.45M.
D
Sell
2/21/2017Upgraded
Basilea Pharmaceutica Ltd. (BPMUF) was upgraded to D from D- on 2/21/2017 due to a substantial increase in the solvency index, growth index and valuation index. Operating cash flow increased 2.53% from -$10.92M to -$10.64M, EBIT increased 2.53% from -$9.77M to -$9.52M, and earnings per share increased from -$1.1846 to -$1.1547.
Basilea Pharmaceutica Ltd. (BPMUF) was upgraded to D from D- on 2/21/2017 due to a substantial increase in the solvency index, growth index and valuation index. Operating cash flow increased 2.53% from -$10.92M to -$10.64M, EBIT increased 2.53% from -$9.77M to -$9.52M, and earnings per share increased from -$1.1846 to -$1.1547.
D
Sell
8/1/2016Downgrade
Basilea Pharmaceutica AG (BPMUF) was downgraded to D- from D on 8/1/2016 due to a significant decline in the volatility index, solvency index and total return index.
Basilea Pharmaceutica AG (BPMUF) was downgraded to D- from D on 8/1/2016 due to a significant decline in the volatility index, solvency index and total return index.
D
Sell
10/30/2015None
Basilea Pharmaceutica AG (BPMUF) was downgraded to D from U on 10/30/2015.
Basilea Pharmaceutica AG (BPMUF) was downgraded to D from U on 10/30/2015.
OTC PK
03/24/2025 2:51PM Eastern
Quotes delayed
